Advancing Science. Enhancing Outcomes.
Developing a novel class of molecules targeting a range of disease pathways.
About Emerald Biotechnology España
At Emerald Health Biotechnology España SLU, we are committed to the discovery and development of new cannabinoid derivatives for improved therapeutic outcomes. We are experts in the screening of hit compounds, and the identification of the mechanism of action and assessment of the efficacy of molecules and phytoextracts for pharmaceutical, nutraceutical, and cosmetic uses. Leveraging decades of experience, we are deeply rooted in several leading European academic institutions, and work closely with some of the most renowned scientists in cannabis research.
We have established a strong patent portfolio protecting our novel candidates that focus on the endocannabinoid system. Emerald Health Biotechnology España has developed a sequential platform of primary and secondary screenings that are able to analyze more than 20 key molecular targets in a range of disease pathways.
With headquarters at the Technological & Scientific Park of Córdoba (Spain), our R&D laboratory is equipped with the best technology for biomedicine research. Working with top-class research centers such as the University of Córdoba (IMIBIC), CIBERNED, the University Complutense of Madrid (IRYCIS), CSIC – (Madrid), and the University of Piamonde Orientale (Italy), we are able to allocate the most appropriate resources, expertise and capabilities to each project.
Projects
Preclinical development of new hydroxamate triterpenoids (RTC-2017-6109-1. Retos-Colaboración 2017 call. Ministry of Science, Innovation and Universities. Spanish Government).
Read MoreManagement
Prof. Dr. Eduardo Muñoz, MD, PhD Founder
Pilar Díaz Espejo-Saavedra, MSc Managing director